Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have been assigned a consensus rating of “Hold” from the seven analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $4.39.

A number of analysts have commented on the company. ValuEngine upgraded Synthetic Biologics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research report on Wednesday, August 9th. Finally, William Blair restated an “outperform” rating and issued a $5.00 price target on shares of Synthetic Biologics in a research report on Monday, May 22nd.

Hedge funds have recently added to or reduced their stakes in the company. Creative Planning boosted its stake in Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after buying an additional 70,000 shares in the last quarter. Susquehanna International Group LLP boosted its stake in Synthetic Biologics by 76.4% in the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock valued at $107,000 after buying an additional 82,030 shares in the last quarter. UBS Group AG boosted its stake in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in Synthetic Biologics during the second quarter valued at about $194,000.

Shares of Synthetic Biologics (NYSEMKT:SYN) opened at 0.635 on Tuesday. Synthetic Biologics has a 12 month low of $0.41 and a 12 month high of $1.90. The company’s market cap is $81.44 million. The stock has a 50 day moving average of $0.55 and a 200-day moving average of $0.62.

Synthetic Biologics (NYSEMKT:SYN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. Equities analysts forecast that Synthetic Biologics will post ($0.17) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Synthetic Biologics Inc (SYN) Given Consensus Rating of “Hold” by Analysts” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/08/29/synthetic-biologics-inc-syn-given-consensus-rating-of-hold-by-analysts.html.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Analyst Recommendations for Synthetic Biologics (NYSEMKT:SYN)

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.